Literature DB >> 16773453

The effects of tacrolimus ointment on regulatory T lymphocytes in atopic dermatitis.

Marzia Caproni1, Daniele Torchia, Emiliano Antiga, Walter Volpi, Elena del Bianco, Paolo Fabbri.   

Abstract

Only very recently studies were conducted in order to evaluate the impact of regulatory T (Treg) cells in the pathophysiology of atopic dermatitis (AD). Nine adult patients with moderate-to-severe AD in riacutization period of a chronic disease were given tacrolimus ointment, while seven hydrocortisone butyrate ointment, that served as controls. We performed lesional-skin biopsies before and after treatment, that were stained immunohistochemically with monoclonal antibodies to CD4, CD25, forkhead/winged helix transcription factor (FoxP3), interleukin (IL)-10 and transforming growth factor (TGF)-beta. CD4+ cells were significantly reduced in post-treatment series. Tacrolimus treatment achieved a significant reduction of CD25+ cells. FoxP3+ cells were present in untreated AD lesions. Both treatments did not significantly modify the number of FoxP3+ cells. The number of IL-10+ cells increased in post-treatment series. Tacrolimus enhanced the production of TGF-beta, while hydrocortisone did not. Restoration of TGF-beta-producing Treg cells may represent another important pharmacodynamic effect of tacrolimus on AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16773453     DOI: 10.1007/s10875-006-9034-2

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  25 in total

Review 1.  Natural versus adaptive regulatory T cells.

Authors:  Jeffrey A Bluestone; Abul K Abbas
Journal:  Nat Rev Immunol       Date:  2003-03       Impact factor: 53.106

2.  Relative impact of CD4+CD25+ regulatory T cells and tacrolimus on inhibition of T-cell proliferation in patients with atopic dermatitis.

Authors:  M Vukmanovic-Stejic; A McQuaid; K E Birch; J R Reed; C Macgregor; M H A Rustin; A N Akbar
Journal:  Br J Dermatol       Date:  2005-10       Impact factor: 9.302

Review 3.  T regulatory cells and allergy.

Authors:  Alison Taylor; Johan Verhagen; Cezmi A Akdis; Mübeccel Akdis
Journal:  Microbes Infect       Date:  2005-04-25       Impact factor: 2.700

4.  Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells.

Authors:  Carla C Baan; Barbara J van der Mast; Mariska Klepper; Wendy M Mol; Annemiek M A Peeters; Sander S Korevaar; Aggie H M M Balk; Willem Weimar
Journal:  Transplantation       Date:  2005-07-15       Impact factor: 4.939

Review 5.  Factors that regulate naturally occurring T regulatory cell-mediated suppression.

Authors:  Elena Goleva; Ivan D Cardona; Liang-Shiou Ou; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2005-11       Impact factor: 10.793

Review 6.  Transforming growth factor beta (TGF-beta) and autoimmunity.

Authors:  Christopher A Aoki; Andrea T Borchers; Ming Li; Richard A Flavell; Christopher L Bowlus; Aftab A Ansari; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2005-09       Impact factor: 9.754

Review 7.  Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.

Authors:  Darren M Ashcroft; Paul Dimmock; Ruth Garside; Ken Stein; Hywel C Williams
Journal:  BMJ       Date:  2005-02-24

8.  Interleukin-10-secreting "regulatory" T cells induced by glucocorticoids and beta2-agonists.

Authors:  Emma J Peek; David F Richards; Alexander Faith; Paul Lavender; Tak H Lee; Christopher J Corrigan; Catherine M Hawrylowicz
Journal:  Am J Respir Cell Mol Biol       Date:  2005-04-21       Impact factor: 6.914

9.  FK506 independently upregulates transforming growth factor beta and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with atopic skin.

Authors:  C-C E Lan; Y-H Kao; S-M Huang; H-S Yu; G-S Chen
Journal:  Br J Dermatol       Date:  2004-09       Impact factor: 9.302

10.  Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen.

Authors:  Birgit Knoechel; Jens Lohr; Estelle Kahn; Jeffrey A Bluestone; Abul K Abbas
Journal:  J Exp Med       Date:  2005-11-14       Impact factor: 14.307

View more
  7 in total

1.  Preventive and therapeutic effects of tacrolimus in an interleukin-10-deficient mouse model of colitis.

Authors:  Yohei Okada; Noriaki Maeda; Shoji Takakura; Keiji Miyata; Masahiro Koshiba
Journal:  Inflamm Res       Date:  2011-08-10       Impact factor: 4.575

2.  Latent simian varicella virus reactivates in monkeys treated with tacrolimus with or without exposure to irradiation.

Authors:  Ravi Mahalingam; Vicki Traina-Dorge; Mary Wellish; Eileen Deharo; Morgan L Singletary; Erin P Ribka; Robert Sanford; Don Gilden
Journal:  J Neurovirol       Date:  2010-10       Impact factor: 2.643

Review 3.  Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+ CD25+ T cells.

Authors:  Guangwei Liu; Yong Zhao
Journal:  Immunology       Date:  2007-10       Impact factor: 7.397

Review 4.  CD4+ regulatory T cells in solid organ transplantation.

Authors:  Fadi Issa; Kathryn J Wood
Journal:  Curr Opin Organ Transplant       Date:  2010-12       Impact factor: 2.640

5.  Successful treatment of plasmacytosis circumorificialis with topical tacrolimus: two case reports and an immunohistochemical study.

Authors:  Taku Fujimura; Sadanori Furudate; Masaya Ishibashi; Yumi Kambayashi; Gen-Ichi Tojo; Chihiro Wakusawa; Hiroshi Mayama; Setsuya Aiba
Journal:  Case Rep Dermatol       Date:  2013-03-20

6.  Successful treatment of granuloma faciale with topical tacrolimus: a case report and immunohistochemical study.

Authors:  Gen-Ichi Tojo; Taku Fujimura; Yumi Kambayashi; Katsuko Kikuchi; Setsuya Aiba
Journal:  Case Rep Dermatol       Date:  2012-07-12

Review 7.  The Role of Toll-Like Receptors in Skin Host Defense, Psoriasis, and Atopic Dermatitis.

Authors:  Lixiang Sun; Wenjie Liu; Ling-Juan Zhang
Journal:  J Immunol Res       Date:  2019-11-14       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.